Introduction {#s1}
============

Immune checkpoint inhibitors have recently gained popularity owing to their efficacy and low toxicity ([@B1]). Immunotherapy, in combination with conventional oncology treatment, can activate the body\'s autoimmune response to recognize tumor cells throughout the body ([@B2]). Radiotherapy has classically been considered a form of local treatment, causing direct damage to DNA in tumor cells. Because some immune cells are inherently sensitive to radiotherapy, radiotherapy also has both immunosuppressive and immunostimulatory activities ([@B3]). Combinations of local radiotherapy and systemic immunotherapy have been shown recently to have significant advantages in preclinical and clinical studies ([@B4]). Some studies have also confirmed that radiotherapy combined with immunotherapy can produce abscopal effects and perhaps what we term a "radio-memory" effect such that the addition of one to the other has synergistic effects ([@B5], [@B6]). Although radiation-induced abscopal effects have been reported in many studies ([@B7]--[@B10]), little is known about the radio-memory effect.

In terms of immunostimulatory effects, localized radiotherapy can stimulate systemic immune responses ([@B3]) by promoting the expression of tumor-associated antigens and the production of new tumor antigens to activate antitumor immune responses, counteracting the tumor\'s ability to inhibit antigen presentation. For instance, MHC-1, a key antigen recognized by CD8+ T cells, is significantly reduced in tumor cells ([@B11]). Radiotherapy can effectively promote the expression of MHC-1, promote the maturation of dendritic cells, and infiltrate tumors ([@B12]); reduce the numbers of Tregulatory cells (Tregs) in tumors; expand T-cell lineages; and enhance T cell migration. Radiotherapy has also been shown to partially or in some cases completely convert non-immunogenic tumors into immunogenic tumors ([@B13]). Radiotherapy in combination with anti-PD1/PDL1 antibodies, anti-CTLA4 antibodies, immune cytokines, dendritic cell vaccines, and Toll-like receptor antagonists can control local tumor progression, thereby improving overall survival (OS) and inducing specific immune responses to cancer ([@B14]).

The KEYNOTE-001 and PACIFIC studies confirmed that having had radiotherapy followed by treatment with a PD1/PDL1 inhibitor could produce a memory-specific immune anti-cancer effect ([@B14], [@B15]). We postulate that this result results from radiotherapy acting as a catalyst or ignition agent that may change a patient\'s overall immune microenvironment; radiotherapy may enhance the production and storage of immune memory cells, which when followed by immunotherapy would amplify the efficacy of the immunotherapy. With the above hypothesis, we evaluated the effects of intrapleural infusion of IL-2 for the treatment of malignant pleural effusions (MPE) caused by lung cancer, particularly whether these effects varied in patients who had received radiotherapy vs. in those who had not. Specifically, we sought to determine whether the radio-memory effect could occur after radiotherapy combined with other immunotherapy agents, or whether this effect is restricted to anti-PD1/PDL1 drugs.

Methods {#s2}
=======

Patients
--------

We retrospectively identified and reviewed records of patients with MPE to identify patients with non-small-cell lung cancer (NSCLC) who had received intrapleural infusion of IL-2 or cisplatin, with or without prior radiotherapy. Patients were aged 18 years or older, had adequate organ function, with no history of pneumonitis, systemic immunosuppressive therapy, or other autoallergic diseases. Efficacy evalution and disease progression were determined with the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. All patients provided written informed consent, and this study was approved by the appropriate institutional review boards. All patients enrolled in our study were treated at one of the following institutions: Shandong Cancer Hospital and Institute; Affiliated Hospital of Weifang Medical University; Weifang People\'s Hospital; Laiwu Chinese Medicine Hospital; and Linyi People\'s Hospital, all in Shandong, China.

Procedures
----------

Patients received intrapleural infusion of one cycle of either IL-2 (20,000 U) or cisplatin alone (40--60 mg) until the effusion progressed. Before this infusion, all patients underwent more than one ultrasound-guided pleural catheterization for drainage to remove as much of the pleural effusion as possible. To ensure the uniform distribution of the agents in the pleural cavity, patients were advised to turn over smoothly every 15 min.

Patients were considered to have a history of radiotherapy if they had received any radiotherapy for NSCLC at any time during the 18 months before the intrapleural treatment. Radiotherapy sites included the lungs or metastases in the thoracic lymph nodes, brain, and other extracranial metastatic sites. Radiotherapy schedules before MPE were categorized as (1) chemotherapy followed by concurrent chemoradiotherapy, (2) upfront concurrent chemoradiotherapy followed by adjuvant chemotherapy, (3) induction chemotherapy followed by sequential radiotherapy, concurrent (4) chemoradiotherapy only, or (5) intracranial radiotherapy. Radiotherapy type was categorized as conventional (i.e., 2-dimensional), three-dimensional conformal radiotherapy, or intensity-modulated radiation therapy.

Data Collection and Evaluation Criteria
---------------------------------------

Clinicopathologic data collected for all patients included sex, age, Eastern Cooperative Oncology Group (ECOG) performance status score, smoking history. Hematologic indicator including total lymphocytic counts, neutrophils and neutrophil--lymphocyte Ratio (NLR) were also collected. Response to treatment (by RECIST v1.1) were evaluated as described elsewhere ([@B7], [@B15], [@B17]). Short-term efficacy was classified as complete response (CR; MPE and symptoms disappeared and the patient\'s condition was stable for \>8 weeks), partial response (PR; MPE size reduced by 50%, symptoms improved, and no subsequent growth in the MPE over 8 weeks), stable disease (SD; MPE size reduced by \< 50% or unchanged), or progressive disease (PD; MPE size increased). The objective response rate (ORR) included both CR and PR, and the disease (MPE) control rate (DCR) included CR, PR, and SD.

Outcomes
--------

The primary objective was to determine whether prior receipt of radiotherapy affected PFS or OS after intrapleural IL-2 or cisplatin treatment. The secondary objective was to determine the effect of previous extracranial radiotherapy on PFS and OS, to account for potential blood-brain barrier effects. Additional objectives included evaluating the effect of previous radiotherapy on treatment efficacy and pulmonary toxicity. Progression-free survival (PFS) was defined as the interval between the initiation of intrapleural IL-2 (or cisplatin) and the time to either effusion progression or death. Overall survival (OS) was measured from the date of the initiation of intrapleural IL-2 to the date of death from any cause or the last known follow-up date.

Statistical Analysis
--------------------

All statistical analyses were done with SPSS (Statistical Package for the Social Sciences) version 17.0 and Prism GraphPad 6.0. Clinicopathologic characteristics and short-term efficacy were analyzed by using χ^2^ tests, Fisher\'s exact tests, or Student\'s *t* tests. Independent predictors associated with PFS and OS were identified by using a Cox regression model. PFS and OS were analyzed with the Kaplan-Meier method, with differences between groups evaluated with log-rank tests. Two-sided *P-*values of \< 0.05 were considered statistically significant.

Results {#s3}
=======

Patient Characteristics
-----------------------

A total of 3,747 patients with MPE were treated at the participating hospitals between August 2009 and February 2015. Of these patients, 1,506 received intrapleural IL-2 and the other 2,241 received intrapleural cisplatin. Among the 1,506 patients given IL-2, 1,098 had NSCLC; after exclusion of 456 patients who survived for \< 6 months after treatment, the study group consisted of 642 patients (Figure [1](#F1){ref-type="fig"}). The control group (i.e., those given intrapleural cisplatin but not IL-2) consisted of 1,102 patients with NSCLC who survived for more than 6 months after treatment. The enrollment flowchart is shown in Figure [1](#F1){ref-type="fig"}, and baseline patient characteristics are shown in Table [1](#T1){ref-type="table"}. The median age of the 642 patients in the study group was 62 years (range 29--87). Most patients had received intrapleural chemotherapy and several lines of systemic therapy before receiving the intrapleural IL-2. Slightly more than half of the 642 patients given IL-2 (324, or 50.5%) had previously received radiotherapy, which was extracranial in 288 (44.8%). The median follow-up for patients alive at this analysis was 38 months. Radiotherapy was delivered for a median period of 6.4 months (range 0.8--85.0, IQR 3.0--15.5), before the first cycle of intrapleural IL-2.

![Flowchart of eligible patients enrolled in this study. From a total of 3,747 patients with malignant pleural effusion (MPE), we identified 1,506 who had been treated with interpleural interleukin-2 (IL-2) and 2,241 who had been treated with intrapleural cisplatin. Of the 1,098 patients given IL-2 (and the 1,875 patients given cisplatin) who had non-small cell lung cancer, 642 who had received IL-2 survived for more than 6 months, and 1,102 who had received cisplatin survived for more than 6 months. Patients in each group were subdivided according to whether they had any vs. no radiotherapy (RT), or extracranial vs. no extracranial RT.](fimmu-09-02916-g0001){#F1}

###### 

Baseline characteristics of 642 patients with non-small cell lung cancer who received IL-2.

  **Variable**                                          **No. of patients**   **Any previous RT**              **Previous extracranial RT**                                                                                             
  ----------------------------------------------------- --------------------- -------------------------------- --------------------------------- ------------------- -------------------------------- --------------------------------- -------------------
                                                                              **No (*****n*** **=** **318)**   **Yes (*****n*** **=** **324)**   ***P*****-Value**   **No (*****n*** **=** **354)**   **Yes (*****n*** **=** **288)**   ***P*****-Value**
  **SEX**                                                                                                                                                                                                                               
  Male                                                  360                   168 (53%)                        192 (59%)                         0.501               198 (56%)                        162 (56%)                         0.974
  Female                                                282                   150 (47%)                        132 (41%)                                             156 (44%)                        126 (44%)                         
  **AGE, YEARS**                                                                                                                                                                                                                        
  ≥55                                                   312                   144 (45%)                        168 (52%)                         0.497               174 (49%)                        138 (48%)                         0.899
  \< 55                                                 330                   174 (55%)                        156 (48%)                                             180 (51%)                        150 (52%)                         
  **ECOG PS SCORE**                                                                                                                                                                                                                     
  0                                                     122                   60 (19%)                         62 (19%)                          0.836               69 (19%)                         53 (18%)                          0.827
  1                                                     412                   204 (64%)                        208 (64%)                                             221 (62%)                        191 (66%)                         
  2                                                     108                   54 (17%)                         54 (17%)                                              60 (18%)                         48 (16%)                          
  **HISTOPATHOLOGIC CLASSIFICATION**                                                                                                                                                                                                    
  Squamous cell                                         198                   90 (28%)                         108 (33%)                         0.573               120 (34%)                        78 (27%)                          0.448
  Adenocarcinoma or other                               444                   228 (72%)                        216 (67%)                                             234 (66%)                        210 (73%)                         
  **SMOKING HISTORY**                                                                                                                                                                                                                   
  Never-smoker                                          402                   210 (66%)                        192 (59%)                         0.469               234 (66%)                        168 (58%)                         0.409
  Former/current smoker                                 240                   108 (34%)                        132 (41%)                                             120 (34%)                        120 (42%)                         
  **DIAGNOSIS METHOD FOR MPE**                                                                                                                                                                                                          
  CT-guided biopsy                                      264                   126 (40%)                        138 (43%)                         0.438               138 (39%)                        126 (44%)                         0.220
  Pleural effusion cytology                             144                   78 (25%)                         66 (20%)                                              90 (25%)                         54 (19%)                          
  Thoracotomy                                           174                   72 (23%)                         102 (31%)                                             78 (22%)                         96 (33%)                          
  Neck lymph node biopsy                                60                    42 (12%)                         18 (6%)                                               48 (14%)                         12 (4%)                           
  **COLOR OF PLEURAL EFFUSION**                                                                                                                                                                                                         
  Bloody                                                426                   222(70%)                         204 (63%)                         0.453               246 (69%)                        180 (63%)                         0.447
  Light yellow                                          216                   96(30%)                          120 (37%)                                             108 (31%)                        108 (37%)                         
  **HEMATOLOGIC FINDINGS**                                                                                                                                                                                                              
  Neutrophil count, mean ± IQR, × 10^3^/μL                                    6.12 ± 1.78                      4.48 ± 1.34                       0.032               6.09 ± 1.81                      4.4 ± 1.32                        0.034
  Total lymphocyte count, mean ± IQR, × 10^3^/μL                              1.34 ± 0.35                      2.21 ± 0.70                       0.021               1.35 ± 0.36                      2.19 ± 0.69                       0.022
  Neutrophil-to-lymphocyte ratio                                              4.56 ± 1.36                      2.06 ± 0.70                       \< 0.01             4.52 ± 1.41                      2.02 ± 0.75                       \< 0.01
  **INTRAPLEURAL CHEMOTHERAPY BEFORE IL-2**                                                                                                                                                                                             
  Yes                                                   528                   270 (85%)                        258 (80%)                         0.766               300 (85%)                        228 (79%)                         0.739
  No                                                    114                   54 (15%)                         60 (20%)                                              54 (15%)                         60 (21%)                          
  History of brain metastases                                                 0                                68 (21%)                          \< 0.01             36 (10%)                         32 (11%)                          0.699
  No. of previous systemic therapies, mean (range)                            2 (0--5)                         2 (0--5)                          0.017               2 (0--5)                         3 (0--6)                          0.017
  **PREVIOUS SYSTEMIC THERAPIES BEFORE IL-2**                                                                                                                                                                                           
  No                                                                          236 (74%)                        250 (77%)                         0.18                259 (73%)                        227 (79%)                         0.096
  Yes                                                                         82 (26%)                         74 (23%)                                              95 (27%)                         61 (21%)                          
  **RADIOTHERAPY SCHEDULE BEFORE DISTANT METASTASIS**                                                                                                                                                                                   
  ChT → CCRT                                                                                                   140 (43%)                                                                              140 (49%)                         
  CCRT → ChT                                                                                                   61 (19%)                                                                               61 (21%)                          
  ChT → RT                                                                                                     66 (20%)                                                                               66 (23%)                          
  CCRT alone                                                                                                   21 (6%)                                                                                21 (7%)                           
  Intracranial radiotherapy                                                                                    36 (12%) 0                                                                             0                                 
  **RADIOTHERAPY TYPE**                                                                                                                                                                                                                 
  Conventional (2D) radiotherapy                                                                               164 (51%)                                                                              148 (52%)                         
  3D-CRT/MRT                                                                                                   160 (49%)                                                                              140 (48%)                         
  **PREVIOUS SABR**                                                                                                                                                                                                                     
  Yes                                                   20                                                     20 (6%)                                                                                20 (7%)                           
  No                                                    622                                                    304 (94%)                                                                              268 (93%)                         

*ECOG, Eastern Cooperative Oncology Group; MPE, malignant pleural effusion; ChT → CCRT, chemotherapy followed by concurrent chemoradiotherapy; CCRT → ChT, upfront concurrent chemoradiotherapy followed adjuvant chemotherapy; ChT → RT, induction chemotherapy followed by sequential radiotherapy; CCRT alone, concurrent chemoradiotherapy alone; IMRT, intensity modulated radiotherapy; 3D-CRT, three dimensional conformal radiotherapy; SBRT, stereotactic body radiotherapy or stereotactic radiosurgery*.

Regardless of whether patients had received prior radiotherapy or not, significant differences were found between groups with regard to sex, age, ECOG status, histopathologic classification, smoking history, diagnosis method, color of MPE, and history of concurrent intrapleural chemotherapy (Table [1](#T1){ref-type="table"}). Patients who had prior radiotherapy had significantly higher frequency of brain metastases and had received more systemic therapies than patients who had not had prior radiotherapy (Table [1](#T1){ref-type="table"}). Frequency of brain metastases was similar among patients who had received extracranial radiotherapy and those who had not had prior extracranial radiotherapy.

Survival Outcomes
-----------------

PFS time was similar among patients given IL-2 regardless of whether they had had prior radiotherapy or not (median PFS time 4.0 months prior vs. 3.67 months no prior, *p* = 0.18; Figure [2A](#F2){ref-type="fig"}). PFS time for patients who received IL-2 preceded by extracranial radiotherapy was longer than that for patients who had not had extracranial radiotherapy (median PFS time 4.06 months extra vs. 3.64 months no extra, *p* = 0.046; Figure [2B](#F2){ref-type="fig"}). Otherwise, previous radiotherapy or previous extracranial radiotherapy did not confer an advantage in PFS for patients with cisplatin (Supplementary Figure [1](#SM1){ref-type="supplementary-material"}). In univariate analysis of the 642 patients who received intrapleural IL-2, ECOG score (*p* = 0.036), previous systemic therapy (*p* = 0.041), previous intrapleural chemotherapy (*P* = 0.049), having had any prior radiotherapy (*p* = 0.019) and having had extracranial radiotherapy (*p* = 0.32) were associated with longer PFS. Multivariate analysis revealed that ECOG score, having had any radiotherapy, and having had extracranial radiotherapy were independent predictors of PFS (Table [2](#T2){ref-type="table"}).

![Effect of previous radiotherapy on progression-free survival and overall survival for patients with IL-2. **(A,B)** Progression-free survival in patients according to a history of **(A)** any radiotherapy or **(B)** extracranial radiotherapy. **(C,D)** Overall survival in patients according to a history of **(C)** any radiotherapy or **(D)** extracranial radiotherapy. Hazard ratios \[HRs\] are shown.](fimmu-09-02916-g0002){#F2}

###### 

Factors associated with progression-free survival.

                                       **PFS**             **Any previous RT and PFS**   **Previous Extracranial RT and PFS**                                           
  ------------------------------------ ------------------- ----------------------------- -------------------------------------- ------------------- ------------------- -------------------
                                       **HR (95% CI)**     ***P*****-Value**             **HR (95% CI)**                        ***P*****-Value**   **HR (95% CI)**     ***P*****-Value**
  Sex (Female vs. male)                1.69 (0.82--2.94)   0.229                                                                                                        
  Age (≥55 y vs. \< 55 y)              0.75 (0.48--1.41)   0.312                                                                                                        
  ECOG PS score (0 vs. 1 vs. 2)        0.71 (0.45--0.82)   0.036                         0.57 (0.23--0.92)                      0.032               0.59 (0.25--0.89)   0.033
  Adenocarcinoma and other                                                                                                                                              
      (vs. squamous)                   1.63 (0.75--2.32)   0.52                                                                                                         
  SMOKING HISTORY                                                                                                                                                       
      (Never vs. former/current)       1.43 (1.00--2.14)   0.051                                                                                                        
  Color of pleural effusions                                                                                                                                            
      (Bloody vs. yellow)              1.12 (0.66--2.43)   0.23                                                                                                         
  Previous systematic therapy          0.56 (0.32--0.91)   0.041                         0.62 (0.25--1.06)                      0.071               0.64 (0.23--1.12)   0.069
  Previous intrapleural chemotherapy                                                                                                                                    
      (Yes vs. no)                     1.65 (1.12--2.32)   0.049                         1.75 (0.87--2.32)                      0.062               1.77 (0.85--2.34)   0.066
  Any previous radiotherapy                                                                                                                                             
      (Yes vs. no)                     0.68 (0.34--0.89)   0.019                         0.65 (0.31--0.87)                      0.024                                   
  Previous extracranial radiotherapy                                                                                                                                    
      (Yes vs. no)                     0.87 (0.64--0.94)   0.032                                                                                    0.84 (0.62--0.91)   0.024

*Progression-free survival was defined as the time from the first dose of intrapleural interkeukin-2 until disease progression or death*.

*HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status*.

As for OS time, among the patients given IL-2, having received any radiotherapy was associated with longer OS time than no radiotherapy (median OS time 8.8 months vs. 7.34 months, *p* = 0.0116; Figure [2C](#F2){ref-type="fig"}), as was having received extracranial radiotherapy compared with no extracranial radiotherapy (median OS time 8.93 months vs. 6.92 months, *p* = 0.0003; Figure [2D](#F2){ref-type="fig"}). Otherwise, previous radiotherapy or previous extracranial radiotherapy did not confer any advantage in OS for patients with cisplatin (Supplementary Figure [1](#SM1){ref-type="supplementary-material"}). In univariate analysis of the 642 patients who received intrapleural IL-2, age (*p* = 0.041), ECOG score (*p* = 0.04), smoking history (*p* = 0.016), previous intrapleural chemotherapy (*p* = 0.046), having received any radiotherapy (*p* = 0.042), and having received extracranial radiotherapy (*p* = 0.013) were associated with longer OS times. Multivariate analysis confirmed that smoking history, receipt of any radiotherapy, and receipt of extracranial radiotherapy were independent predictors of OS (Table [3](#T3){ref-type="table"}).

###### 

Factors associated with overall survival.

                                       **OS**              **Any previous RT and OS**   **Previous extracranial RT and OS**                                           
  ------------------------------------ ------------------- ---------------------------- ------------------------------------- ------------------- ------------------- -------------------
                                       **HR (95% CI)**     ***P*** **Value**            **HR (95% CI)**                       ***P*** **Value**   **HR (95% CI)**     ***P*** **Value**
  Sex (Female vs. Male)                1.34 (0.74--2.81)   0.381                                                                                                      
  Age (≥55 y vs. \< 55 y)              0.87 (0.61--0.98)   0.041                        0.9 (0.82--1.00)                      0.056               0.93 (0.84--1.00)   0.063
  ECOG PS score (0 vs. 1 vs. 2)        0.61 (0.36--0.92)   0.04                         0.51 (0.32--0.94)                     0.073               0.52 (0.3--0.91)    0.072
  Adenocarcinoma and other                                                                                                                                            
      (vs. squamous)                   1.85 (0.86--2.93)   0.23                                                                                                       
  Smoking history                                                                                                                                                     
      (Never vs. former/current)       1.76 (1.09--2.42)   0.016                        1.79 (1.09--2.45)                     0.015               1.78 (1.09--2.44)   0.015
  Color of Pleural effusions                                                                                                                                          
      (Bloody vs. yellow)              1.26 (0.64--2.56)   0.49                                                                                                       
  Previous systemic therapy            0.74 (0.36--0.92)   0.15                                                                                                       
  Previous intrapleural chemotherapy                                                                                                                                  
      (Yes vs. no)                     1.81 (1.03--2.54)   0.046                        1.92 (0.91--2.35)                     0.074               1.96 (0.83--2.49)   0.062
  Any previous radiotherapy                                                                                                                                           
      (Yes vs. no)                     0.52 (0.31--0.93)   0.042                        0.56 (0.30--0.85)                     0.045                                   
  Previous extracranial radiotherapy                                                                                                                                  
      (Yes vs. no)                     0.44 (0.24--0.86)   0.013                                                                                  0.36 (0.16--0.82)   0.022

*Overall survival was defined as the time from the first dose of intrapleural interkeukin-2 until disease progression or death. OS, overall survival; HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status*.

Hematologic Outcomes
--------------------

Patients who had had any previous radiotherapy had higher TLC than patients with no prior radiotherapy (1.34 ± 0.35 vs. 2.21 ± 0.70, *p* = 0.021); had lower neutrophil counts than patients with no prior radiotherapy (6.12 ± 1.78 vs. 4.48 ± 1.34, *p* = 0.032); and had lower NLR than patients with no prior radiotherapy (4.56 ± 1.36 vs. 2.06 ± 0.70, *p* \< 0.01). These patterns also held for patients who had had extracranial radiotherapy vs. no extracranial radiotherapy (TLC: 6.09 ± 1.81 vs. 4.4 ± 1.32, *p* = 0.034; neutrophils: 1.35 ± 0.36 vs. 2.19 ± 0.69, *p* = 0.022); and NLR: 4.52 ± 1.41 vs. 2.02 ± 0.75, *p* \< 0.01).

Treatment Efficacy
------------------

Short-term treatment efficacy did not differ substantially between patients who had had any radiotherapy and those who had not had any radiotherapy. Treatment outcomes were also no different between patients who had extracranial radiotherapy vs. no extracranial radiotherapy (Table [4](#T4){ref-type="table"}).

###### 

Short-term treatment efficacy for patients with intrapleural IL-2.

                               **Previous radiotherapy**   **Previous extracranial radiotherapy**                                                                           
  ---------------------------- --------------------------- ---------------------------------------- ------------------- ------------------------- ------------------------- -------------------
                               **No**                      **Yes**                                  ***P*** **Value**   **No**                    **Yes**                   ***P*** **Value**
                               **(*****n*** **= 318)**     **(*****n*** **= 324)**                                      **(*****n*** **= 354)**   **(*****n*** **= 288)**   
  Complete response, no.       16                          20                                       0.529               18                        18                        0.585
  Partial response, no.        140                         139                                      0.317               145                       134                       0.157
  Stable disease, no.          60                          52                                       0.347               63                        49                        0.797
  Disease control rate         67.92                       65.12                                    0.452               63.84                     69.79                     0.112
  Objective response rate, %   49.06                       49.07                                    0.669               46.05                     52.78                     0.0897

Discussion {#s4}
==========

Preclinical and clinical studies have shown that radiotherapy can enhance antitumor immune responses. A secondary analysis of the KEYNOTE-001 phase 1 trial, in particular, suggested that previous radiotherapy may improve the outcomes of patients given pembrolizumab relative to those for patients not given radiotherapy. Here we sought to determine whether radiotherapy combined with another well-known immune agent would produce similar radio-memory effect. In our retrospective analysis of outcomes among patients given intrapleural IL-2 or cisplatin for MPE in light of prior receipt of radiotherapy for NSCLC, we found that having received radiotherapy before IL-2 led to longer PFS and OS times compared with patients who had not had prior radiotherapy. No such results were found for patients given cisplatin but not IL-2. We further found that patients who had had any prior radiotherapy or prior extracranial radiotherapy had higher TLC, lower neutrophil counts, and lower NLR than those who had no prior radiotherapy which generally are associated with better treatment efficacy and longer survival ([@B16], [@B17]). To our knowledge, this was the largest such analysis undertaken to date, and its results strongly suggest that having had radiotherapy may improve the efficacy of immune therapy other than checkpoint inhibitors. These findings are consistent with the results of several preclinical studies indicating significant, synergistic antitumor effects achieved by combining radiotherapy with immunotherapy. Our findings thus seem to demonstrate that combining radiotherapy with immunotherapy other than the previously studied anti-PD1/PDL1 can indeed induce a "radio-memory" effect.

IL-2, also known as T-cell growth factor, includes a range of bioactive cytokines produced primarily by activated CD4+ T cells and CD8+ T cells, acts as a growth factor for all T-cell subsets and can also promote the activation of B-cell proliferation ([@B18], [@B19]). IL-2 is also important in the regulation of the immune response, including antibody responses, hematopoiesis, and tumor surveillance. Numerous animal models have shown that combining radiotherapy with IL-2 has a synergistic antitumor effect ([@B20]--[@B23]) and has been shown to be useful clinically in oral cancer ([@B24]), renal cell carcinoma ([@B25]), and prostate cancer ([@B26]). Our results are consistent with these studies. In a study published in 2011, Koji suggested that radiotherapy combined with IL-2 may have radiopharmaceutical effects ([@B27]); however, to our knowledge, no studies to date have demonstrated a radio-memory effect.

In our study, patients given intrapleural IL-2 who had previously received radiotherapy for NSCLC had better OS than those who had not had radiotherapy (*p* = 0.0116, Figure [2C](#F2){ref-type="fig"}), but no differences were found in short-term efficacy or PFS between these to groups (*p* = 0.18, Figure [2A](#F2){ref-type="fig"}). We further found better PFS and OS among patients who had received extracranial irradiation than among those who had not received extracranial irradiation (*p* = 0.046, Figure [2B](#F2){ref-type="fig"}; *p* = 0.0003, Figure [2D](#F2){ref-type="fig"}). These findings may reflect the following. First, compared to extracranial radiotherapy, cranial radiotherapy will damage more lymphocyte cells and some believe that cranial irradiation cannot change the immune microenvironment in the brain ([@B28]). Second, the immune microenvironment within the brain may not change because of the presence of the blood-brain barrier. Even if such changes in the immune system did occur within the brain, it is unlikely that this effect would extend to the immune microenvironment throughout the body, as the blood-brain barrier serves as an obstacle.

Typically the choice of radiation dose, distribution, sequence, and target area is made to ensure thorough destruction of tumor cells while minimizing damage to surrounding normal tissues. When radiotherapy is used as an intervention for immunization, however, this classical approach may require adjustment. For example, it may not be necessary to include the entire tumor area to high-dose radiation, because exposing only a part of the tumor may be required to trigger the immune system. Radiation dose and segmentation schemes that trigger an immune response probably depend on many unknown factors, but the required dose is likely to be much lower than the dose required for definitive radiotherapy, which would in turn reduce the likelihood of adverse reactions. Finally, proton therapy may be more suitable than photon therapy for combining with immune therapy, as proton therapy doses are usually lower and protons may have an as-yet unrecognized role in immunotherapy. However, more comprehensive research in this area is required before recommendations can be made.

Our study of patients with NSCLC who also developed MPE involved a large number of patients with which to analyze the overall clinical effect of previous radiotherapy when those patients were given IL-2. Nevertheless, our study had several limitations, chief among them its retrospective nature, with the attendant unclear inclusion criteria and somewhat inaccurate statistical analyses. Second, the effects on the clinical endpoints studied (OS and PFS) were relatively modest, and the statistical significance levels were marginal. Third, our data could not shed light on the mechanism underlying the radio-memory effect of previous radiotherapy. Also, it is possible that bias may have been introduced by differences in standards of living among patients, perhaps including distance from and access to radiotherapy facilities. Overall, although this study could be considered hypothesis-generating; its conclusions should be validated through prospective controlled trials. From surgery to medicine, and from radiotherapy to immunotherapy, many approaches have been attempted to eradicate cancer. However, single treatments have had relatively modest success at best, and hence the greatest challenge faced by modern-day oncologists is to identify the optimal combinations of existing forms of cancer therapy.

Conclusions {#s5}
===========

Our findings suggest that previous receipt of radiotherapy for NSCLC may enhance the efficacy of IL-2 for treating MPE and improve outcomes for such patients. They further suggest that the radio-memory effect is not restricted to combining radiotherapy with PD1/PDL1 inhibitors but may extend to other immunotherapy agents. Future clinical trials involving radiotherapy and immunotherapy should consider this observation in designing more rational regimens.
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###### 

Effect of previous radiotherapy on progression-free survival and overall survival for patients with Cisplatin. **(A,B)** Progression-free survival in patients according to a history of **(A)** any radiotherapy or **(B)** extracranial radiotherapy. **(C,D)** Overall survival in patients according to a history of **(C)** any radiotherapy or **(D)** extracranial radiotherapy. Hazard ratios \[HRs\] are shown.

###### 

Click here for additional data file.

NSCLC

:   non-small cell lung cancer

IL-2

:   interleukin-2

MPE

:   malignant pleural effusion

ECOG

:   Eastern Cooperative Oncology Group

SBRT

:   stereotactic ablative radiotherapy or radiosurgery

CR

:   complete response

PR

:   partial response

SD

:   stable disease

DCR

:   disease control rate

ORR

:   objective response rate.
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